Singapore markets closed
Straits Times Index
3,306.02 +6.02 (+0.18%) Nikkei
38,596.47 -36.55 (-0.09%) Hang Seng
18,028.52 -306.80 (-1.67%) FTSE 100
8,237.72 -34.74 (-0.42%) Bitcoin USD
64,322.74 -738.62 (-1.14%) CMC Crypto 200
1,325.69 -34.64 (-2.55%)
BIIB Jan 2025 450.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 09:30AM EDT. Market open.
| Previous close | 0.2000 |
| Open | 0.2000 |
| Bid | 0.0500 |
| Ask | 2.0000 |
| Strike | 450.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.2000 - 0.2000 |
| Contract range | N/A |
| Volume | |
| Open interest | 77 |
ZacksIonis (IONS) Expands Licensing Deal With Otsuka for HAE Drug
Ionis (IONS) out-licenses the rights for its HAE drug to Otsuka in the Asia-Pacific region. The companies signed a similar deal last year granting Otsuka rights to market the drug in Europe.
ZacksAlzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab (Revised)
If Eli Lilly's (LLY) donanemab is approved by the FDA, it will become the second drug approved by the FDA to reduce the clinical decline associated with Alzheimer's disease.
ZacksThe Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune (Revised)
Biogen, Eli Lilly's, Prothena and AC Immune are included in this Analyst Blog.
© 2024 Yahoo. All rights reserved.